Perturbations in gut microbiota composition in schizophreniaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined the composition and function of the gut microbiota in people with schizophrenia. Researchers used both 16S rRNA gene sequencing and whole-genome shotgun metagenomic sequencing to characterize microbial diversity, taxonomic composition, and functional gene content. The aim was to explore how gut microbes, acting through the gut-brain axis, might relate to this severe and complex psychiatric disorder.
Who was studied?
The study included 29 patients diagnosed with schizophrenia and 30 age-matched normal controls. This is a relatively small clinical cohort, and the abstract does not specify additional demographic details such as sex distribution, geographic location, or illness duration. Both 16S rRNA and metagenomic sequencing were performed on samples from these same participants.
What were the most important findings?
Patients with schizophrenia had higher abundances of the bacterial genera Clostridium and Megasphaera compared to controls. Functional analysis linked schizophrenia to alterations in sphingolipid metabolism, phosphonate and phosphinate metabolism, and glutamine metabolism. These findings were consistent across both the 16S rRNA and metagenomic sequencing approaches. The abstract does not mention Desulfovibrio, sulfate-reducing bacteria, hydrogen sulfide, or sulfur metabolism.
What are the greatest implications of this study?
The findings support the idea that the gut microbiota has a measurable effect on schizophrenia, reinforcing the relevance of the gut-brain axis to this disorder. Specific taxa such as Clostridium and Megasphaera, along with the identified metabolic pathways, may serve as leads for future mechanistic or biomarker research. These results provide a foundation for further investigation into microbiome-based understanding or management of schizophrenia.